Sarepta shares fall 37% as FDA questions future of key gene therapy

Shares of Sarepta Therapeutics fell close to 37% on Friday after reports emerged that the US Food and Drug Administration is considering whether to halt the distribution of Elevidys, the company’s flagship gene therapy for Duchenne Muscular Dystrophy (DMD). The move comes amid an ongoing investigation into multiple patient deaths tied to Sarepta’s gene therapy […]